Opdivo ads vs. the reality of stage IV cancer treatment
Is it ok for journalists to attend Bayer-funded training on new cancer treatments?
Flying under journalists’ radars: brain-enhancing supplements dubbed ‘nootropics’
The hospital-media partnership: promoting public health or inducing public demand?
Trans-Pacific trade pact’s pharma provisions lack media scrutiny
Why the media must play a bigger role in policing unsafe medical devices
How fast to “cures” and at what cost? Politico forum tilts toward pharma-friendly messaging
Sponsored content, new cholesterol drugs, and the political process
Was Turing Pharmaceuticals’ 5000% price increase a tipping point?
Another potentially troubling “partnership” between a news org & Mayo Clinic